Overall, SIRT3 protects GBM cells from ferroptosis through mechanisms involving mitophagy and the regulation of SLC7A11, making it a promising therapeutic target in combination with ferroptosis induction for treating glioblastoma [90]. The gene discussed is SLC7A11; the disease is glioblastoma.